| 5.78 0.14 (2.48%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7 | 1-year : | 8.18 |
| Resists | First : | 6 | Second : | 7 |
| Pivot price | 5.69 |
|||
| Supports | First : | 5.44 | Second : | 5.11 |
| MAs | MA(5) : | 5.67 |
MA(20) : | 5.63 |
| MA(100) : | 5.04 |
MA(250) : | 4.82 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 66.9 |
D(3) : | 63 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 6.94 | Low : | 2.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FHTX ] has closed below upper band by 25.5%. Bollinger Bands are 67.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.84 - 5.86 | 5.86 - 5.89 |
| Low: | 5.38 - 5.41 | 5.41 - 5.43 |
| Close: | 5.73 - 5.78 | 5.78 - 5.83 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Wed, 04 Mar 2026
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tue, 24 Feb 2026
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Tue, 24 Feb 2026
Cancer-focused biotech Foghorn to present at two March investor forums - Stock Titan
Mon, 23 Feb 2026
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Mon, 23 Feb 2026
Ryan Maynard joins Foghorn Therapeutics (NASDAQ: FHTX) as new CFO - Stock Titan
Mon, 23 Feb 2026
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 21.5 (%) |
| Held by Institutions | 71.7 (%) |
| Shares Short | 1,210 (K) |
| Shares Short P.Month | 1,130 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.6 |
| Profit Margin | -294.2 % |
| Operating Margin | -227 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4.4 % |
| Gross Profit (p.s.) | -1.02 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -5.08 |
| PEG Ratio | 0 |
| Price to Book value | -3.64 |
| Price to Sales | 13.8 |
| Price to Cash Flow | -3.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|